A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: Comparison with native t-PA

被引:35
作者
Kawai, C
Yui, Y
Hosoda, S
Nobuyoshi, M
Suzuki, S
Sato, H
Takatsu, F
Motomiya, T
Kanmatsuse, K
Kodama, K
Yabe, Y
Minamino, T
Kimata, SI
Nakashima, M
Sugiyama, M
Sone, T
Hiasa, Y
Kijima, M
Nakamura, N
Hayasaki, K
Abe, H
Kadowaki, K
Murayama, H
Joh, T
Katagiri, T
Watanabe, S
Dohi, K
Tateda, K
Murata, M
Hayashida, N
Arita, M
Sakai, K
Kita, T
Toda, H
Meguro, T
Harada, M
Higuma, N
Nagai, T
Takizawa, A
Hirayama, H
Murakami, E
Hirose, K
Ishise, S
Shimomura, K
Inada, M
Chino, M
Hiramori, K
Yokoyama, K
Munakata, T
Takase, S
机构
[1] KYOTO UNIV HOSP, KYOTO 606, JAPAN
[2] TOKYO WOMENS MED COLL, TOKYO 162, JAPAN
[3] KOKURA MEM HOSP, KITAKYUSHU, FUKUOKA, JAPAN
[4] SAKAKIBARA HEART INST, TOKYO, JAPAN
[5] HIROSHIMA CITY HOSP, HIROSHIMA, JAPAN
[6] ANJO KOSEI HOSP, ANJO, AICHI, JAPAN
[7] TOKYO METROPOLITAN HIROO GEN HOSP, TOKYO, JAPAN
[8] NIHON UNIV, SURUGADAI HOSP, TOKYO, JAPAN
[9] OSAKA POLICE HOSP, OSAKA, JAPAN
[10] TOHO UNIV, SCH MED, TOKYO, JAPAN
[11] SAKURABASHI WATANABE HOSP, OSAKA, JAPAN
[12] TOKYO WOMENS MED COLL, AOYAMA HOSP, TOKYO 162, JAPAN
[13] HAMAMATSU UNIV SCH MED, HAMAMATSU, SHIZUOKA 43131, JAPAN
关键词
D O I
10.1016/S0735-1097(97)00074-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This prospective, randomized, double-blind multicenter trial evaluated the efficacy and safety of a single bolus injection of the novel modified tissue-type plasminogen activator (t-PA) E6010 in the treatment of acute myocardial infarction compared with that of native t-PA. Background. E6010 is a novel modified t-PA with a prolonged half-life (t(1/2) alpha greater than or equal to 23 min) compared with native t-PA (t(1/2) alpha = 4 min). E6010 can be administered in patients as a single intravenous bolus injection, and early recanalization can be expected. Methods. The efficacy of E6010 was compared with that of native t-PA in 199 patients,vith acute myocardial infarction who were treated within 6 h of onset in a prospective, randomized, double-blind multicenter trial. Patients were given either 0.22 mg/kg body weight of E6010 intravenously over 2 min or native t-PA (tisokinase) 28.8 mg or 14.4 million IU (10% of the total dose over 1 to 2 min, the remainder infused over 60 min). Results. The primary end point was the recanalization rate of the infarct-related coronary artery at 60 min after the start of treatment. Time to reperfusion was shorter in the E6010 group than in the native t-PA group. Thrombolysis in Myocardial Infarction how grade 2 or 3 recanalization at 15, 30, 45 and 60 min after administration was observed in 37%, 62%, 74% and 79% (95% confidence interval [CI] 70% to 87%) of the E6010-treated patients and in 14%, 32%, 50% and 65% (95% CI 55% to 74%) of native t-PA-treated patients, respectively (p = 0.032 at 60 min). Conclusions. The present study indicates that, compared with native t-PA, a single bolus injection of E6010 over 2 min produces a higher rate of early recanalization of the infarct-related coronary artery without fatal bleeding complications. (C) 1997 by the American College of Cardiology.
引用
收藏
页码:1447 / 1453
页数:7
相关论文
共 23 条
[1]  
[Anonymous], 1986, LANCET, V1, P397
[2]   EVALUATION OF COMBINATION THROMBOLYTIC THERAPY AND TIMING OF CARDIAC-CATHETERIZATION IN ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THROMBOLYSIS AND ANGIOPLASTY IN MYOCARDIAL-INFARCTION PHASE-5 RANDOMIZED TRIAL [J].
CALIFF, RM ;
TOPOL, EJ ;
STACK, RS ;
ELLIS, SG ;
GEORGE, BS ;
KEREIAKES, DJ ;
SAMAHA, JK ;
WORLEY, SJ ;
ANDERSON, JL ;
HARRELSONWOODLIEF, L ;
WALL, TC ;
PHILLIPS, HR ;
ABBOTTSMITH, CW ;
CANDELA, RJ ;
FLANAGAN, WH ;
SASAHARA, AA ;
MANTELL, SJ ;
LEE, KL .
CIRCULATION, 1991, 83 (05) :1543-1556
[3]   RANDOMIZED ANGIOGRAPHIC TRIAL OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (ALTEPLASE) IN MYOCARDIAL-INFARCTION [J].
CARNEY, RJ ;
MURPHY, GA ;
BRANDT, TR ;
DALEY, PJ ;
PICKERING, E ;
WHITE, HJ ;
MCDONOUGH, TJ ;
VERMILYA, SK ;
TEICHMAN, SL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (01) :17-23
[4]   THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE [J].
CHESEBRO, JH ;
KNATTERUD, G ;
ROBERTS, R ;
BORER, J ;
COHEN, LS ;
DALEN, J ;
DODGE, HT ;
FRANCIS, CK ;
HILLIS, D ;
LUDBROOK, P ;
MARKIS, JE ;
MUELLER, H ;
PASSAMANI, ER ;
POWERS, ER ;
RAO, AK ;
ROBERTSON, T ;
ROSS, A ;
RYAN, TJ ;
SOBEL, BE ;
WILLERSON, J ;
WILLIAMS, DO ;
ZARET, BL ;
BRAUNWALD, E .
CIRCULATION, 1987, 76 (01) :142-154
[5]  
DATI F, 1987, THROMB HAEMOSTASIS, V58, P856
[6]  
ELMS MJ, 1983, THROMB HAEMOSTASIS, V50, P591
[7]  
FRIBERGER P, 1978, HAEMOSTASIS, V7, P138
[8]   A PROSPECTIVE, RANDOMIZED TRIAL COMPARING COMBINATION HALF-DOSE TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND STREPTOKINASE WITH FULL-DOSE TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
GRINES, CL ;
NISSEN, SE ;
BOOTH, DC ;
GURLEY, JC ;
CHELLIAH, N ;
WOLF, R ;
BLANKENSHIP, J ;
BRANCO, MC ;
BENNETT, K ;
DEMARIA, AN .
CIRCULATION, 1991, 84 (02) :540-549
[9]  
HIROSAWA K, 1991, JPN PHARMACOL THER, V19, P1003
[10]   INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - A REPORT FROM THE MULTICENTER THROMBOLYSIS TRIAL [J].
KANEMOTO, N ;
GOTO, Y ;
HIROSAWA, K ;
KAWAI, C ;
KIMATA, S ;
YUI, Y ;
YAMAMOTO, Y .
JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1990, 54 (01) :71-81